Prof. Jinjun Shi
Jinjun Shi, Ph.D.
Associate Professor
Harvard Medical School
Center for Nanomedicine
Brigham and Women’s Hospital
Boston 02115, MA, USA
Tel: +1-617-525-8798
Email: jshi@bwh.harvard.edu
Jinjun Shi is an Associate Professor at Harvard Medical School and a faculty member in the Center for Nanomedicine at Brigham and Women’s Hospital. He received his PhD degree from the Department of Chemistry at Texas A&M University in May 2008. His research involves a highly interdisciplinary combination of nanotechnology, biomaterials, drug delivery, immunotherapy, and antioxidative therapy. In particular, his laboratory is interested in the rational development of innovative biomaterials and nanoparticle platforms for effective delivery of biomacromolecules (such as siRNA, mRNA, and protein) and for biomedical applications in cancer, inflammatory diseases, and others. He has authored over 55 peer-reviewed papers and is an inventor of over 45 issued/pending patents worldwide. He has also received many awards, such as the NIH K99/R00 career development award from National Cancer Institute, the Movember Challenge Award (2013) and Young Investigator Award (2014) from the Prostate Cancer Foundation, and the Concept Award (2018) from the Department of Defense Congressionally Directed Medical Research Programs.
Representative Publications:
1. Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope1 H, Yu M, Cao W, Oswald JT, Dinarvand M, Mahmoudi M, Langer R, Kantoff PK, Farokhzad OC*, Zetter BR*, Shi J*. Restoration of Tumour-Growth Suppression In Vivo via Systemic Nanoparticle-Mediated Delivery of PTEN mRNA. Nat Biomed Eng 2018; 2:850-64.
2. Liu Y, Ji X, Tong WWL, Askhatova D, Yang T, Cheng HW, Wang YZ, Shi J*. Engineering Multifunctional RNAi Nanomedicine to Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angew Chem Int Ed 2018; 57:1510-13.
3. Xu X, Saw PE, Tao W, Li Y, Ji X, Yu M, Mahmoudi M, Rasmussen J, Ayyash D, Zhou Y, Farokhzad OC*, Shi J*. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett 2017; 17(7):4427-35.
4. Liu Y, Ai K, Ji X, Askhatova D, Du R, Lu L*, Shi J*. Comprehensive Insights into the Multi-Antioxidative Mechanisms of Melanin Nanoparticles and Their Application to Protect Brain from Injury in Ischemic Stroke. J Am Chem Soc. 2017; 139(2):856-62.
5. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer Nanomedicine: Progress, Challenges and Opportunities. Nat Rev Cancer 2017; 17:20-37.
6. Zhu X, Xu YJ, Solis LM, Tao W, Wang LZ, Behrens C, Xu XY, Zhao LL, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J*. Long-Circulating RNAi Nanoparticles for Validating PHB1-Targeted Non-Small Cell Lung Cancer Treatment. Proc Natl Acad Sci U S A 2015; 112:7779-84.
Associate Professor
Harvard Medical School
Center for Nanomedicine
Brigham and Women’s Hospital
Boston 02115, MA, USA
Tel: +1-617-525-8798
Email: jshi@bwh.harvard.edu
Jinjun Shi is an Associate Professor at Harvard Medical School and a faculty member in the Center for Nanomedicine at Brigham and Women’s Hospital. He received his PhD degree from the Department of Chemistry at Texas A&M University in May 2008. His research involves a highly interdisciplinary combination of nanotechnology, biomaterials, drug delivery, immunotherapy, and antioxidative therapy. In particular, his laboratory is interested in the rational development of innovative biomaterials and nanoparticle platforms for effective delivery of biomacromolecules (such as siRNA, mRNA, and protein) and for biomedical applications in cancer, inflammatory diseases, and others. He has authored over 55 peer-reviewed papers and is an inventor of over 45 issued/pending patents worldwide. He has also received many awards, such as the NIH K99/R00 career development award from National Cancer Institute, the Movember Challenge Award (2013) and Young Investigator Award (2014) from the Prostate Cancer Foundation, and the Concept Award (2018) from the Department of Defense Congressionally Directed Medical Research Programs.
Representative Publications:
1. Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope1 H, Yu M, Cao W, Oswald JT, Dinarvand M, Mahmoudi M, Langer R, Kantoff PK, Farokhzad OC*, Zetter BR*, Shi J*. Restoration of Tumour-Growth Suppression In Vivo via Systemic Nanoparticle-Mediated Delivery of PTEN mRNA. Nat Biomed Eng 2018; 2:850-64.
2. Liu Y, Ji X, Tong WWL, Askhatova D, Yang T, Cheng HW, Wang YZ, Shi J*. Engineering Multifunctional RNAi Nanomedicine to Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angew Chem Int Ed 2018; 57:1510-13.
3. Xu X, Saw PE, Tao W, Li Y, Ji X, Yu M, Mahmoudi M, Rasmussen J, Ayyash D, Zhou Y, Farokhzad OC*, Shi J*. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett 2017; 17(7):4427-35.
4. Liu Y, Ai K, Ji X, Askhatova D, Du R, Lu L*, Shi J*. Comprehensive Insights into the Multi-Antioxidative Mechanisms of Melanin Nanoparticles and Their Application to Protect Brain from Injury in Ischemic Stroke. J Am Chem Soc. 2017; 139(2):856-62.
5. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer Nanomedicine: Progress, Challenges and Opportunities. Nat Rev Cancer 2017; 17:20-37.
6. Zhu X, Xu YJ, Solis LM, Tao W, Wang LZ, Behrens C, Xu XY, Zhao LL, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J*. Long-Circulating RNAi Nanoparticles for Validating PHB1-Targeted Non-Small Cell Lung Cancer Treatment. Proc Natl Acad Sci U S A 2015; 112:7779-84.
分享